PDCD1 and neoplasm: To further explore a more potent antitumor effect for mechanistic study and potential clinical application, we employed two immunotherapy regimens, which consist of anti-PD-1 as an example of checkpoint blockade therapy or PC7A nanovaccine for T cell therapy22 in three murine tumor models.